AstraZeneca is in preliminary talks to acquire $Bristol-Myers Squibb(BMY)$ in a potential $400 billion mega-merger. While unconfirmed talks spark immediate speculative upside for BMY, regulatory scrutiny over overlapping oncology pipelines means traders should expect elevated volatility rather than a guaranteed buyout.
Thank you for your LIKE and FOLLOW. I heard you, TIGERSSS. Option Comm Free Vouchers are available for you. Contact me before it ends.
IF YOU ALREADY OWN THE SHARES
If you hold 100 or more shares of BMY, you can consider selling covered calls (selling the right for someone else to buy your shares at a specified target price to collect upfront income) out-of-the-money.
-
With BMY trading near $65.31 and underlying implied volatility (IV, the market's expectation of future price movement) holding around 31%, options premiums are inflated.
-
Selling the September 4th $68.00 Call allows you to harvest roughly $1.14 to $1.66 in premium per share.
-
This strategy generates immediate yield while establishing a hedged exit point if the merger rumors cool off or hit regulatory roadblocks.
IF YOU WANT TO OWN THE SHARES
If you want to acquire BMY at a discount while monetizing the current headline momentum, consider selling a cash-secured put (setting aside cash to buy shares at a lower price while earning immediate option premium).
-
The key technical support level sits firmly around $62.00–$63.00.
-
Selling the September 4th $63.00 Put collects roughly $1.13 to $1.51 in premium per share.
-
If BMY stays above $63.00 by expiration, you keep the cash premium outright; if it falls below, your effective purchase price drops to around $61.50–$61.87, safety-cushioned well below current trading levels.
IF YOU JUST WANT TO TRADE FOR PROFIT
For traders looking to play the elevated volatility without taking underlying equity risk, a defined-risk call debit spread (buying a call option while simultaneously selling a higher strike call to offset cost) limits your maximum loss while capturing potential upside spikes.
-
Buy the September 4th $66.00 Call and sell the September 4th $69.00 Call for a net debit cost around $1.00–$1.20.
-
This limits your downside risk strictly to the net premium paid while providing leverage toward the $69.00 resistance level if buyout momentum continues.
-
This setup avoids direct exposure to an abrupt IV crush (a sharp drop in option premiums once headline uncertainty resolves) compared to purchasing outright call options.
EDUCATIONAL DISCLAIMER
This post is for educational and informational purposes only and does not constitute financial advice. Options involve significant risk and are not suitable for all investors. Always conduct your own research and assess your personal risk tolerance before trading.
Comments